45
Participants
Start Date
August 31, 2006
Primary Completion Date
August 31, 2008
Study Completion Date
May 31, 2011
Bortezomib (VELCADE)
1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
Rituximab
375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
Gruppo Italiano Studio Linfomi, Modena
Gruppo Italiano Studio Linfomi
OTHER